GAD65, GAD67, and GABAT Immunostaining in Human Brain and Apparent GAD65 Loss in Alzheimer's Disease
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The GABAergic system is the main inhibitory neurotransmitter system in the vertebrate brain. Although it is well established that the GABAergic system is affected in neuropsychiatric disorders, in Alzheimer's disease (AD) it has been considered to be relatively spared. In this study we describe the immunohistochemical localization of the main enzymes of the GABAergic system; glutamate decarboxylase 65 (GAD65), GAD67, and GABA transferase (GABAT) in human brain. In neocortex, hippocampus, basal ganglia, and cerebellum, GAD65 and GAD67 immunoreactivity were found in neuropil granules, possibly axonal boutons or terminals, and in a subset of small to midsized neurons. GAD65 preferentially stained neuropil granules, while GAD67 preferentially stained neuronal cell bodies. GABAT intensely labeled many types of neurons and glia cells. While GAD65 and GAD67 stained the cytoplasm of cells homogeneously, GABAT labeling appeared irregular and granular. GAD65 immunoreactivity of neurons and neuropil was severely reduced in AD middle temporal gyrus, hippocampus, and putamen as determined by fluorescence and light microscopic immunohistochemistry. Western blotting revealed a similar reduction of GAD65, but not GAD67, protein levels in the middle temporal gyrus of AD. Our results suggest that the GABAergic system is more severely affected in AD than previously reported. This deficit may contribute to AD pathogenesis by loss of GABAergic inhibitory activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 2×
“, 2012 [35]: (A) amyloid- score, (B) neurofibrillary tangle score, (C) neuritic plaque score, (n) no, (l) low, (i) intermediate and (h) high”
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613 · cited 1×
“Decreased GABAergic inhibition could contribute to widespread hyperactivity such as reported in recent fMRI studies in mild cognitive impairment cases [84–87].”
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017
Inhibitory role for GABA in autoimmune inflammation
Bhat, R., Axtell, R., Mitra, A., Miranda, M., Lock, C., Tsien, R. W., & Steinman, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915139107 · Cited by 509
Hashimoto, T., Arion, D., Unger, T., Maldonado-Avilés, J. G., Morris, H. M., Volk, D. W., Mirnics, K., & Lewis, D. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002011 · Cited by 490
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703806104 · Cited by 483 · cited 1×
“as well as schizophrenia [11–14].”
Heckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., & Benes, F. M. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.521 · Cited by 322
Yates, C. M., Butterworth, J., Tennant, M. C., & Gordon, A. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04948.x · Cited by 263
GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders
Sibille, E., Morris, H. M., Kota, R. S., & Lewis, D. A. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001616 · Cited by 217
Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900705 · Cited by 191 · cited 2×
“In Alzheimer’s disease (AD), the GABAergic system has long been considered relatively spared and only affected late in the disease process (for reviews see [20–23]).”
Wang, A. Y., Lohmann, K. M., Yang, C. K., Zimmerman, E. I., Pantazopoulos, H., Herring, N., Berretta, S., Heckers, S., & Konradi, C. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0881-4 · Cited by 135
Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals
Honer, W. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.005 · Cited by 135
Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease
Takahashi, H., Brasnjevic, I., Rutten, B. P. F., Van Der Kolk, N., Perl, D. P., Bouras, C., Steinbusch, H. W. M., Schmitz, C., Hof, P. R., & Dickstein, D. L. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0242-4 · Cited by 124 · cited 3×
“The reduction in the density of GAD65 IR neurons reported in our study may correlate with the previously described loss of calbindin, parvalbumin, or calretinin-containing (GABAergic) interneurons in AD, transgenic mouse models and aging dogs [25–29, 37, 81, 82].”
Krantic, S., Isorce, N., Mechawar, N., Davoli, M. A., Vignault, E., Albuquerque, M., Chabot, J.-G., Moyse, E., Chauvin, J.-P., Aubert, I., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110830 · Cited by 78 · cited 1×
“Impairment of the GABAergic system has also been shown in transgenic mouse models of AD: loss of GAD67 IR hippocampal neurons in TgCRND8 [74] and loss of GABAergic markers in a MRI study of PSA PP mice [75].”
Popović, M., Caballero-Bleda, M., Kadish, I., & Van Groen, T. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.023 · Cited by 38 · cited 1×
“The reduction in the density of GAD65 IR neurons reported in our study may correlate with the previously described loss of calbindin, parvalbumin, or calretinin-containing (GABAergic) interneurons in AD, transgenic mouse models and aging dogs [25–29, 37, 81, 82].”
Cited by
Wu, Z., Guo, Z., Gearing, M., & Chen, G. (2014) · Nature Communications · doi:10.1038/ncomms5159 · Cited by 306
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081813 · Cited by 208
“Component Methodology Subregion Change Comments References GAT1 [3H]tiagabine radioligand binding Frontal cortex ↔ [244] Temporal cortex IHC Superior temporal gyrus ↓ Observed across both regions,and also in astrocytes specifically [218]Entorhinal cortex GAT3 IHC Superior temporal gyrus ↔ Large, non-significantdownreg…”
BackgroundInfluentialGABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis
Carello-Collar, G., Bellaver, B., Ferreira, P. C. L., Ferrari-Souza, J. P., Ramos, V. G., Therriault, J., Tissot, C., De Bastiani, M. A., Soares, C., Pascoal, T. A., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02140-w · Cited by 98
“The meta-analyses of individual brain regions revealed lower levels of GABA in the temporal and frontal cortices and cerebellum.”
InfluentialJiang, S., Wen, N., Li, Z., Dube, U., Del Aguila, J., Budde, J., Martinez, R., Hsu, S., Fernandez, M. V., Cairns, N. J., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0319-z · Cited by 73
Metadata
- Authors
- Schwab, C., Yu, S., Wong, W., McGeer, E. G., & McGeer, P. L.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2013-01-21
- Volume
- 33
- Issue
- 4
- Pages
- 1073-1088
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1484999790
- Cited by
- 68
- References
- 18
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.